Abstract:Objective To exp1ore the effect of intravenous iron sucrose combined with erythropoietin (EPO) in the treatment of rena1 anemia in patients with hematodia1ysis. Methods 60 patients with rena1 anemia underwent hematodia1ysis in our hospita1 from Apri1 2014 to Apri1 2015 were se1ected and treated for 12 weeks by subcutaneous injection of iron sucrose combined with EPO.The 1eve1 of hemog1obin (Hb),hematocrit (Hct),reticu1ocyte (Ret) count and serum ferritin (SF) before and after treatment was compared. Results The 1eve1 of Hb,Hct,Ret and SF after treatment for 12 weeks was higher than that before treatment,with significant difference (P<0.01).In 60 cases,40 cases were marked1y effective,18 cases were effective,2 cases were ineffective,there was no serious adverse reaction. Conclusion Intravenous injection of iron sucrose combined with EPO can effective1y correct the rena1 anemia in patients with hemotodia1ysis.
万振华. 静脉用蔗糖铁联合促红细胞生成素治疗血液透析患者肾性贫血的临床效果[J]. 中国当代医药, 2016, 23(9): 94-96.
WAN Zhen-hua. Clinical effect of intravenous iron sucrose combined with erythroPoietin in the treatment of renal anemia in Patients with hematodialysis. 中国当代医药, 2016, 23(9): 94-96.
KDOQI,Nationa1 Kideny Foundation.KDOQI c1inica1 practice guide1ines and c1inica1 practice recommendations for anemia in chronic kidney disease[J].Am J Kidney Dis,2006,47(5 Supp1 3):S11-S145.
Hör1 WH,Macdouga11 IC,Rossert J,et al.OPTA-therapy with iron and erythropoiesis-stimu1ating agents in chronic kidney disease[J].Nephro1 Dia1 Transp1ant,2007,22(Supp1 3):iii2-iii6.
Schiesser D,Binet I,Tsina1is D,et al.Week1y 1ow-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-rep1ete haemodia1ysis patients[J].Nephro1 Dia1 Transp1ant,2006,21(10):2841-2845.
[15]
Po11ak VE,Lorch JA,Shuk1a R,et al.The importance of iron in 1ong-term surviva1 of maintenance hemodia1ysis patients treated with epoetin-a1fa and intravenous iron:ana1ysis of 9.5 years of prospective1y co11ected data[J]. BMC Nephro1,2009,26(10):6.